ReviewThe Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians2023
Vonoprazan: A New Potassium-Competitive Acid Blocker.
Review in The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Assessing the non-inferiority of a 10-day compared with a 14-day vonoprazan-amoxicillin dual therapy regimen for H. pylori eradication: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Vonoprazan attenuates proteinuria in diabetic kidney disease through potential direct renal mechanism.Scientific reports · 2025Trial
- Pharmacokinetics, mass balance, and metabolism of the novel potassium-competitive acid blocker JP-1366 in healthy Chinese adults following a single oral dose of [Frontiers in pharmacology · 2025Trial
- Pecan nut-derived carbon quantum dots-modified electrode for sensitive electrochemical determination of vonoprazan using a green analytical approach.Scientific reports · 2026Article
- Effects of Vonoprazan on Isolated Rat Lower Esophageal Sphincter and Ileum.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Article
- Article
- Efficacy and Cost-Effectiveness of Vonoprazan-Amoxicillin Dual Therapy Versus Esomeprazole-Bismuth Quadruple Therapy forMicroorganisms · 2026Article
- Gastrointestinal symptoms and disorders of gut-brain interaction in pregnancy.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Review
- Determinants ofBMJ open · 2026Article
- Efficacy of Vonoprazan-Doxycycline Dual Therapy for the Treatment ofInfection and drug resistance · 2026Article
- Optimizing acid-related disease management: insights into potassium-competitive acid blockers and proton pump inhibitors.European journal of clinical pharmacology · 2025Review
- Smartphone-assisted HPTLC for simultaneous determination of vonoprazan fumarate and aspirin: a comparative study with HPTLC densitometry.Scientific reports · 2025Article
- Controversies in management of Helicobacter pylori infection from a U.S. perspective: population screening and treatment.Minerva gastroenterology · 2025Review
- Proton Pump Inhibitors (PPIs)-An Evidence-Based Review of Indications, Efficacy, Harms, and Deprescribing.Medicina (Kaunas, Lithuania) · 2025Review
- Potassium-competitive acid blocker has more negative impacts on clinical outcomes in patients with non-small cell lung cancer treated with checkpoint inhibitors than those of proton pump inhibitors.International journal of clinical oncology · 2025Article
- Advances in Gastroesophageal Reflux Disease Management: Exploring the Role of Potassium-Competitive Acid Blockers and Novel Therapies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Mind the gut: Navigating the complex landscape of gastroprotection in neurosurgical patients.World journal of gastroenterology · 2025Article
- Risks of anti-World journal of gastroenterology · 2025Article
- Pharmacodynamics, pharmacokinetics, interactions with other drugs, toxicity and clinical effectiveness of proton pump inhibitors.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.